BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 3907315)

  • 1. A comparison of the acute hemodynamic effects of prostacyclin and hydralazine in primary pulmonary hypertension.
    Groves BM; Rubin LJ; Frosolono MF; Cato AE; Reeves JT
    Am Heart J; 1985 Dec; 110(6):1200-4. PubMed ID: 3907315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic effects of urapidil in patients with pulmonary hypertension. A comparative study with hydralazine.
    Adnot S; Defouilloy C; Brun-Buisson C; Abrouk F; Piquet J; Lemaire F
    Am Rev Respir Dis; 1987 Feb; 135(2):288-93. PubMed ID: 3813189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral hydralazine therapy for primary pulmonary hypertension.
    Rubin LJ; Peter RH
    N Engl J Med; 1980 Jan; 302(2):69-73. PubMed ID: 7350435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension.
    Nootens M; Schrader B; Kaufmann E; Vestal R; Long W; Rich S
    Chest; 1995 Jan; 107(1):54-7. PubMed ID: 7813311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute effect of hydralazine administration on pulmonary artery hemodynamics in dogs with chronic heartworm disease.
    Atkins CE; Keene BW; McGuirk SM; Sato T
    Am J Vet Res; 1994 Feb; 55(2):262-9. PubMed ID: 8172418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic effects of nifedipine versus hydralazine in primary pulmonary hypertension.
    Fisher J; Borer JS; Moses JW; Goldberg HL; Niarchos AP; Whitman HH; Mermelstein M
    Am J Cardiol; 1984 Sep; 54(6):646-50. PubMed ID: 6475787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vasodilator agents in pulmonary artery hypertension of systemic scleroderma].
    Phlippoteau C; Brenot F; Blétry O; Simmonneau G; Duroux P
    Rev Mal Respir; 1990; 7(3):249-54. PubMed ID: 2114030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic effects of oxdralazine and hydralazine in hypertension.
    Moskowitz RM; Cohn JN
    Clin Pharmacol Ther; 1980 Jun; 27(6):773-8. PubMed ID: 7379444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension.
    Barst RJ
    Chest; 1986 Apr; 89(4):497-503. PubMed ID: 2869919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside.
    Kieler-Jensen N; Lundin S; Ricksten SE
    J Heart Lung Transplant; 1995; 14(3):436-43. PubMed ID: 7654728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
    McLaughlin VV; Genthner DE; Panella MM; Rich S
    N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemodynamic response to intravenous hydralazine in patients with pulmonary hypertension.
    McGoon MD; Seward JB; Vlietstra RE; Choo MH; Moyer TP; Reeder GS
    Br Heart J; 1983 Dec; 50(6):579-85. PubMed ID: 6652000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic effects of vasodilators on pulmonary hypertension in decompensated chronic obstructive pulmonary disease.
    Cerdá E; Esteban A; de la Cal MA; Fernández A; García A
    Crit Care Med; 1985 Apr; 13(4):221-3. PubMed ID: 3979067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic comparison of primary venous or arteriolar dilatation and the subsequent effect of furosemide in left ventricular failure after acute myocardial infarction.
    Nelson GI; Silke B; Forsyth DR; Verma SP; Hussain M; Taylor SH
    Am J Cardiol; 1983 Nov; 52(8):1036-40. PubMed ID: 6637819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin, and nifedipine in experimental porcine pulmonary hypertension.
    Prielipp RC; McLean R; Rosenthal MH; Pearl RG
    Crit Care Med; 1991 Jan; 19(1):60-7. PubMed ID: 1986891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamics at rest and during exercise after oral hydralazine in patients with cor pulmonale.
    Rubin LJ; Peter RH
    Am J Cardiol; 1981 Jan; 47(1):116-22. PubMed ID: 7457397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative actions of hydralazine, nifedipine and amrinone in primary pulmonary hypertension.
    Rich S; Ganz R; Levy PS
    Am J Cardiol; 1983 Nov; 52(8):1104-7. PubMed ID: 6637831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic effect of hydralazine in interstitial lung disease patients with cor pulmonale. Immediate and short-term evaluation at rest and during exercise.
    Lupi-Herrera E; Seoane M; Verdejo J; Gomez A; Sandoval J; Barrios R; Martinez W
    Chest; 1985 May; 87(5):564-73. PubMed ID: 3987368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic effects of intravenous hydralazine in pregnant women with severe hypertension.
    Kuzniar J; Skret A; Piela A; Szmigiel Z; Zaczek T
    Obstet Gynecol; 1985 Oct; 66(4):453-8. PubMed ID: 4047535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol.
    Rossi R; Coppi F; Sgura F; Monopoli D; Boriani G
    Pulm Pharmacol Ther; 2018 Apr; 49():147-151. PubMed ID: 28642014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.